LENSAR (NASDAQ:LNSR – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare LENSAR to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, earnings, risk and valuation.
Risk & Volatility
LENSAR has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, LENSAR’s peers have a beta of 2.58, suggesting that their average share price is 158% more volatile than the S&P 500.
Profitability
This table compares LENSAR and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENSAR | 56.07% | 1,254.25% | 49.13% |
| LENSAR Competitors | -270.28% | -155.47% | -22.38% |
Earnings and Valuation
This table compares LENSAR and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| LENSAR | $60.08 million | -$34.28 million | -12.50 |
| LENSAR Competitors | $1.89 billion | $136.81 million | 5.72 |
LENSAR’s peers have higher revenue and earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
40.2% of LENSAR shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 65.8% of LENSAR shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and target prices for LENSAR and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENSAR | 1 | 0 | 2 | 0 | 2.33 |
| LENSAR Competitors | 4310 | 10598 | 18377 | 838 | 2.46 |
LENSAR presently has a consensus price target of $11.00, indicating a potential upside of 120.00%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.28%. Given LENSAR’s higher possible upside, research analysts plainly believe LENSAR is more favorable than its peers.
Summary
LENSAR peers beat LENSAR on 7 of the 13 factors compared.
About LENSAR
LENSAR, Inc. develops and markets laser-based technology for ophthalmic surgery, with a focus on procedures used to treat cataracts. Its systems are designed to assist surgeons with key steps in cataract surgery, including the creation of incisions and the fragmentation of the eye’s natural lens. The company’s products include the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System, which use imaging and software to support surgical planning and treatment. LENSAR also offers related software, accessories and services for ophthalmic practices and surgical facilities.
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
